Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents

References

• Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010;16:3–10.
   PubMed Web of Science ®Google Scholar
• Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015;7:287ra70. doi:10.1126/scitranslmed.aad3106.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Gudgeon CJ, Harrington KH, Dell’Aringa J, Newhall KJ, Means GD, Sinclair AM, Kischel R, Frankel SR, Walter RB. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123:554–561. doi:10.1182/blood-2013-09-527044.
   PubMed Web of Science ®Google Scholar
• Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncol. 2013;9:527–539. doi:10.2217/fon.12.203.
   PubMed Web of Science ®Google Scholar
• Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol. 2016;40:24–35. doi:10.1016/j.coi.2016.02.006.
   PubMed Web of Science ®Google Scholar
• Trivedi A, Stienen S, Zhu M, Li H, Yuraszeck T, Gibbs J, Heath T, Loberg R, Kasichayanula S. Clinical pharmacology and translational aspects of bispecific antibodies. Clin Transl Sci. 2017;10:147–162. doi:10.1111/cts.12459.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28:143–153. doi:10.1016/j.blre.2014.04.001.
   PubMed Web of Science ®Google Scholar
• Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2:4. doi:10.1186/2050-7771-2-4.
   PubMedGoogle Scholar
• Pu YS, Huang CY, Kuo YZ, Kang WY, Liu GY, Huang AM, Yu HJ, Lai MK, Huang SP, Wu WJ, et al. Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma. J Biomed Sci. 2009;16:82. doi:10.1186/1423-0127-16-82.
   PubMed Web of Science ®Google Scholar
• Klein C, Neumann C, Fauti T, Weinzierl T, Freimoser-Grundschober A, Waldhauer I, Fahrni L, Herter S, van Puijenbroek E, Colombetti S, et al. Abstract 3629: Engineering a novel asymmetric head-to-tail 2+1 T-cell bispecific (2+1 TCB) IgG antibody platform with superior T-cell killing compared to 1+1 asymmetric TCBs. Cancer Research. 2017;77:3629. doi:10.1158/1538-7445.AM2017-3629.
   Google Scholar
• Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and clinical development of bispecific t-cell engaging antibodies for cancer treatment. Clin Pharmacol Ther. 2017;101:634–645. doi:10.1002/cpt.651.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838–847. doi:10.1016/j.drudis.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Chiu ML, Gilliland GL. Engineering antibody therapeutics. Curr Opin Struct Biol. 2016;38:163–173. doi:10.1016/j.sbi.2016.07.012.
   PubMed Web of Science ®Google Scholar
• Cao Y, Axup JY, Ma JS, Wang RE, Choi S, Tardif V, Lim RK, Pugh HM, Lawson BR, Welzel G, et al. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers. Angew Chem Int Ed Engl. 2015;54:7022–7027. doi:10.1002/anie.201500799.
   PubMed Web of Science ®Google Scholar
• Lum LG, Thakur A. Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs. 2011;25:365–379. doi:10.2165/11595950-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Chen X, Haddish-Berhane N, Moore P, Clark T, Yang Y, Li H, Xuan D, Barton HA, Betts AM, Barletta F. Mechanistic projection of first-in-human dose for bispecific immunomodulatory P-Cadherin LP-DART: an integrated PK/PD modeling approach. Clin Pharmacol Ther. 2016;100:232–241. doi:10.1002/cpt.393.
   PubMed Web of Science ®Google Scholar
• Hosseini I, Gadkar K, Stefanich E, Li CC, Sun L, Chu YW, Ramanujan S. Systems pharmacology modeling to support clinical development of anti-CD20/CD3 T-cell dependent bispecific antibody. The eighth American Conference on Pharmacometrics; 2016; Seattle, WA.
   Google Scholar
• Campagne O, Delmas A, Fouliard S, Chenel M, Chichili GR, Li H, Alderson R, Scherrmann JM, Mager DE. Integrated pharmacokinetic/pharmacodynamic model of a bispecific CD3xCD123 DART(R) molecule in nonhuman primates: evaluation of activity and impact of immunogenicity. Clin Cancer Res. 2018;24:2631–2641. doi:10.1158/1078-0432.CCR-17-2265.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115:98–104. doi:10.1002/ijc.20908.
   PubMed Web of Science ®Google Scholar
• Skipper HE, Perry S. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res. 1970;30:1883–1897.
   PubMed Web of Science ®Google Scholar
• Westera L, Drylewicz J, Den Braber I, Mugwagwa T, van der Maas I, Kwast L, Volman T, van de Weg-Schrijver EH, Bartha I, Spierenburg G, et al. Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans. Blood. 2013;122:2205–2212. doi:10.1182/blood-2013-03-488411.
   PubMed Web of Science ®Google Scholar
• Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121:1165–1174. doi:10.1182/blood-2012-06-438002.
   PubMed Web of Science ®Google Scholar
• Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002;100:690–697. doi:10.1002/ijc.10557.
   PubMed Web of Science ®Google Scholar
• Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Kohnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016;30:484–491. doi:10.1038/leu.2015.214.
   PubMed Web of Science ®Google Scholar
• Durben M, Schmiedel D, Hofmann M, Vogt F, Nubling T, Pyz E, Bühring HJ, Rammensee HG, Salih HR, Große-Hovest L, et al. Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia. Mol Ther. 2015;23:648–655. doi:10.1038/mt.2015.2.
   PubMed Web of Science ®Google Scholar
• Chen X, Dennis MS, Ebens AJ, Junttila TT, Kelley RF, Mathieu MA, Sun LL. Anti-cd3 antibodies and methods of use. Google patent: Genentech, Inc, South San Francisco, CA; 2015.
   Google Scholar
• Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B, Bargou RC. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95:2098–2103.
   PubMed Web of Science ®Google Scholar
• Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, Hanakam F, Baeuerle PA, Bommert K, Karawajew L, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia. 2003;17:900–909. doi:10.1038/sj.leu.2402890.
   PubMed Web of Science ®Google Scholar
• Harms BD, Kearns JD, Iadevaia S, Lugovskoy AA. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods. 2014;65:95–104. doi:10.1016/j.ymeth.2013.07.017.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A. 2013;110:5145–5150. doi:10.1073/pnas.1220145110.
   PubMed Web of Science ®Google Scholar
• Wuellner U, Klupsch K, Buller F, Attinger-Toller I, Santimaria R, Zbinden I, Henne P, Grabulovski D, Bertschinger J, Brack S. Bispecific CD3/HER2 targeting FynomAb induces redirected T cell-mediated cytolysis with high potency and enhanced tumor selectivity. Antibodies. 2015;4:426. doi:10.3390/antib4040426.
   Web of Science ®Google Scholar
• Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Blinatumomab, a bispecific T-cell engager (BiTE((R))) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin Pharmacokinet. 2016;55:1271–1288. doi:10.1007/s40262-016-0405-4.
   PubMed Web of Science ®Google Scholar
• d’Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, Suzich J, Locher M, Kiener P, Kufer P, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res. 2009;33:465–473. doi:10.1016/j.leukres.2008.08.025.
   PubMed Web of Science ®Google Scholar
• Zhu M, Kratzer A, Johnson J, Holland C, Brandl C, Singh I, Wolf A, Doshi S. Blinatumomab pharmacodynamics and exposure-response relationships in relapsed/refractory acute lymphoblastic leukemia. J Clin Pharmacol. 2018;58:168–179. doi:10.1002/jcph.1006.
   PubMed Web of Science ®Google Scholar
• Szabolcs P, Park KD, Reese M, Marti L, Broadwater G, Kurtzberg J. Absolute values of dendritic cell subsets in bone marrow, cord blood, and peripheral blood enumerated by a novel method. Stem Cells. 2003;21:296–303. doi:10.1634/stemcells.21-3-296.
   PubMed Web of Science ®Google Scholar
• Horny HP, Wehrmann M, Griesser H, Tiemann M, Bultmann B, Kaiserling E. Investigation of bone marrow lymphocyte subsets in normal, reactive, and neoplastic states using paraffin-embedded biopsy specimens. Am J Clin Pathol. 1993;99:142–149.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–847. doi:10.1056/NEJMoa1609783.
   PubMed Web of Science ®Google Scholar
• Wu CP, Qing X, Wu CY, Zhu H, Zhou HY. Immunophenotype and increased presence of CD4(+)CD25(+) regulatory T cells in patients with acute lymphoblastic leukemia. Oncol Lett. 2012;3:421–424. doi:10.3892/ol.2011.499.
   PubMed Web of Science ®Google Scholar
• Nicholas NS, Apollonio B, Ramsay AG. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. Biochim Biophys Acta. 2016;1863:471–482. doi:10.1016/j.bbamcr.2015.11.003.
   PubMed Web of Science ®Google Scholar
• Vilchis-Ordonez A, Contreras-Quiroz A, Vadillo E, Dorantes-Acosta E, Reyes-Lopez A, Quintela-Nunez Del Prado HM, Venegas-Vàzquez J, Mayani H, Ortiz-Navarrete V, López-Martínez B, et al. Bone marrow cells in acute lymphoblastic leukemia create a proinflammatory microenvironment influencing normal hematopoietic differentiation fates. Biomed Res Int. 2015;2015:386165. doi:10.1155/2015/386165.
   PubMedGoogle Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974–977. doi:10.1126/science.1158545.
   PubMed Web of Science ®Google Scholar
• Ginaldi L, de Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51:364–369.
   PubMed Web of Science ®Google Scholar
• Weng WK, Jarvis L, LeBien TW. Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human B cell precursors. J Biol Chem. 1994;269:32514–32521.
   PubMed Web of Science ®Google Scholar
• Wolf ML, Weng WK, Stieglbauer KT, Shah N, LeBien TW. Functional effect of IL-7-enhanced CD19 expression on human B cell precursors. J Immunol. 1993;151:138–148.
   PubMed Web of Science ®Google Scholar
• Benjamin JE, Stein AS. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016;7:142–156. doi:10.1177/2040620716640422.
   PubMed Web of Science ®Google Scholar
• Sgouros G, Stabin M, Erdi Y, Akabani G, Kwok C, Brill AB, Wessels B. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys. 2000;27:2150–2164. doi:10.1118/1.1288393.
   PubMed Web of Science ®Google Scholar
• Zhu M, Kratzer A, Johnson J, Holland C, Brandl C, Singh I, Wolf A, Doshi S. Pharmacokinetics/pharmacodynamics of blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia. American Society of Clinical Oncology 2015 annual meeting; 2015; Chicago, IL.
   Google Scholar
• Molhoj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol. 2007;44:1935–1943. doi:10.1016/j.molimm.2006.09.032.
   PubMed Web of Science ®Google Scholar
• Zhang L, Hou Y, Zhang J, Hu J, Zhang K. Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells. Oncol Lett. 2013;5:1826–1832. doi:10.3892/ol.2013.1281.
   PubMed Web of Science ®Google Scholar
• Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017;31:1743–1751. doi:10.1038/leu.2016.388.
   PubMed Web of Science ®Google Scholar
• Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood. 2016;127:122–131. doi:10.1182/blood-2014-05-575704.
   PubMed Web of Science ®Google Scholar
• Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, et al. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res. 2007;67:3927–3935. doi:10.1158/0008-5472.CAN-06-2760.
   PubMed Web of Science ®Google Scholar
• Root A, Cao W, Li B, LaPan P, Meade C, Sanford J, Macy Jin, Cliona O’Sullivan, Emma Cummins, Matthew Lambert, et al. Development of PF-06671008, a highly potent anti-P-cadherin/Anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer. Antibodies. 2016;5:6. doi:10.3390/antib5010006.
   Web of Science ®Google Scholar
• Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, Clark V, Hristopoulos M, Cook R, Slaga D, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by Anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31:383–395. doi:10.1016/j.ccell.2017.02.001.
   PubMed Web of Science ®Google Scholar
• Nguyen XD, Eichler H, Dugrillon A, Piechaczek C, Braun M, Kluter H. Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. J Immunol Methods. 2003;275:57–68.
   PubMed Web of Science ®Google Scholar
• Cao Y, Balthasar JP, Jusko WJ. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2013;40:597–607. doi:10.1007/s10928-013-9332-2.
   PubMed Web of Science ®Google Scholar
• Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, Wahl J, Hoffmann P, Kischel R, Kvesic M, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014;13:1549–1557. doi:10.1158/1535-7163.MCT-13-0956.
   PubMed Web of Science ®Google Scholar
• Zheng S, Moores S, Jarantow S, Pardinas J, Chiu M, Zhou H, Wang W. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. MAbs. 2016;8:551–561. doi:10.1080/19420862.2015.1136762.
   PubMed Web of Science ®Google Scholar
• Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241–257. doi:10.1016/j.cmpb.2005.04.005.
   PubMed Web of Science ®Google Scholar
• Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72–79. doi:10.1016/j.cmpb.2010.04.018.
   PubMed Web of Science ®Google Scholar